UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inco ...

KemPharm, Inc. (KMPH) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President-Investor Relations & Corporate Communications Travis Mickle - President & Chief Executive Officer Perry Sternberg - Chief Executive Officer, Corium Inc. LaDuane Clifton - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the KemPharm Second Quarter 2020 Corporate and Financial Results Confere ...

Company Overview - KemPharm is focused on developing and commercializing treatments for rare CNS, neurodegenerative, and lysosomal storage diseases[7] - The company has a diverse product portfolio with clinical-stage pipeline assets, revenue-generating NDA-stage assets, and commercial assets[7] - KemPharm's strategic focus is on CNS/rare diseases, with potential for internal commercialization[15] Arimoclomol (Niemann-Pick Disease Type C) - KemPharm acquired arimoclomol, an NDA-stage drug candidate for Niemann-Pick disease type C (NPC), for $128 million[24] - The French EAP for arimoclomol is expected to generate revenue exceeding $12 million in FY 2022[22, 24] - The company plans to resubmit the NDA for arimoclomol in NPC as early as Q1 2023[15, 39] KP1077 (Idiopathic Hypersomnia) - KP1077 is being developed for the treatment of Idiopathic Hypersomnia (IH), a high-value opportunity with significant unmet need[16] - A Phase 1 clinical trial assessing the cardiovascular safety of SDX (KP1077) is expected to have topline results in Q3 2022[59] - Approximately 37,000 patients are diagnosed with IH and actively seeking treatment[46, 68] AZSTARYS® (ADHD) - AZSTARYS® is a partnered medication for ADHD, providing ongoing revenue potential from royalties and milestones[7, 17] - Over 110 million commercial and Medicaid lives have access to AZSTARYS as of March 1, 2021[79] Financial Position - As of March 31, 2022, KemPharm had $1191 million in cash, cash equivalents, marketable securities, and long-term investments[17, 84, 90] - The company's cash runway extends beyond 2025[17, 84, 90]

Management Presentation March 2022 11 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," ...

KemPharm, Inc. (KMPH) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Travis Mickle - Co-Founder, President, CEO & Director LaDuane Clifton - CFO, Secretary & Treasurer Conference Call Participants Jason Rando - Tiberend Strategic Advisors Operator Thank you for standing by, and welcome to the KemPharm First Quarter 2022 Results Conference Call. [Operator Instructions]. I would now like to hand the call over to your host, Jason Rando with Tiberend Strategic Advisors. Please go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inc ...

KemPharm, Inc. (KMPH) Q4 2021 Earnings Conference Call March 30, 2022 5:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President and CEO LaDuane Clifton - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Operator Thank you for standing by, and welcome to KemPharm Fourth Quarter and Year-End 2021 Results Conference Call. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions] I would now like ...

Commission File No. 001-36913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identifi ...

KemPharm, Inc. (KMPH) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Jason Rando – Tiberend Strategic Advisors Travis Mickle – President and Chief Executive Officer LaDuane Clifton – Chief Financial Officer Rich Pascoe – Executive Chairman Conference Call Participants Operator Good day and thank you for standing by. Welcome to the KemPharm Third Quarter 2021 Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of ...